Morgan Stanley downgraded Erasca (ERAS) to Equal Weight from Overweight with a price target of $2, down from $4. The firm sees better opportunities in the space after Erasca announced its fifth reprioritization with plans to seek a strategic partner to further develop naporafenib. The company is not expected to report initial clinical data until 2026, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ERAS: